Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering
-
Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
-
Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
-
Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
-
UPDATE: Hemispherx Biopharma (HEB) Prices 6.6M Share Registered Direct Offering at Approx. $0.39/Sh (Premium to Market)
-
Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market
-
Unusual 11 Mid-Day Movers 9/8: (RADA) (MGAM) (BKYF) Higher; (VII) (ESYS) (DGLY) Lower
-
Morning Movers 08/23: (HAIN) (CALX) (TWER) Higher; (BIG) (GES) (BWEN) Lower
-
Maxim Group Upgrades Hemispherx (HEB) to Buy

